Comparative Pharmacology
Head-to-head clinical analysis: PEPCID versus TRITEC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PEPCID versus TRITEC.
PEPCID vs TRITEC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine H2 receptors on gastric parietal cells, reducing basal and stimulated gastric acid secretion by inhibiting cyclic AMP generation.
H2-receptor antagonist; competitively inhibits histamine at H2 receptors of gastric parietal cells, reducing basal and stimulated gastric acid secretion.
20 mg orally twice daily or 40 mg orally once daily at bedtime for duodenal ulcer; 40 mg orally once daily at bedtime for gastric ulcer; 20 mg orally once daily for GERD; 20 mg orally twice daily for erosive esophagitis; 20 mg intravenously every 12 hours for hospitalized patients with pathological hypersecretory conditions.
300 mg orally twice daily for 14 days; alternative: 600 mg orally once daily for 14 days.
None Documented
None Documented
Terminal elimination half-life: 2.5-3.5 hours in normal renal function; prolonged to 8-10 hours in moderate renal impairment (CrCl 10-50 mL/min) and 15-20 hours in severe impairment (CrCl <10 mL/min); no significant change in hepatic impairment.
2-3 hours (prolonged to 4-5 hours in elderly or renal impairment, CrCl <30 mL/min)
Renal: ~65-70% unchanged via tubular secretion (active) and glomerular filtration; hepatic metabolism (S-oxidation) ~30%; fecal: <5%.
Renal: 60% unchanged; fecal: 35% (mainly metabolites)
Category C
Category C
H2 Receptor Antagonist
H2 Receptor Antagonist/Antimicrobial Combination